v3.26.3
Subsequent Events (Details) - Gilead Sciences, Inc. - Subsequent Event
$ / shares in Units, $ in Millions
Oct. 09, 2026
USD ($)
$ / shares
shares
Subsequent Event [Line Items]  
Sale of stock (in shares) | shares 1,765,486
Sale of stock (in USD per share) | $ / shares $ 14.16
Net proceeds received $ 25.0
Proceeds from equity investment 25.0
Upfront payments 90.0
Payments received from collaborative arrangements 65.0
Potential near-term preclinical milestones 45.0
Maximum further development, regulatory and commercial milestones $ 1,740.0